Medical Equipment

Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market Is Contributing To Changes In The Non-Alcoholic Steatohepatitis Biomarkers Market

April 14, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Non-Alcoholic Steatohepatitis Biomarkers Market Over The 2026–2030 Period? _x000D_

The non-alcoholic steatohepatitis biomarkers market size has experienced significant growth in recent years. It is projected to expand from $1.68 billion in 2025 to $2.08 billion in 2026, at a compound annual growth rate (CAGR) of 23.2%. This historical growth can be attributed to factors such as the increasing prevalence of metabolic disorders, the rising incidence of obesity and type 2 diabetes, the expansion of liver disease research programs, the availability of advanced diagnostic assays, and growing pharmaceutical interest in nash therapies._x000D_

_x000D_

The non-alcoholic steatohepatitis biomarkers market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $4.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. This market growth during the forecast period is driven by increasing investments in precision hepatology, a rising demand for non-invasive diagnostic tools, the expansion of biomarker-driven clinical trials, the growing adoption of personalized medicine approaches, and an increased focus on early-stage disease management. Major trends for the forecast period include the increasing development of non-invasive diagnostic biomarkers, the rising use of serum-based nash biomarkers, the growing integration of AI in biomarker analysis, the expansion of companion diagnostics in drug development, and an enhanced focus on early disease detection._x000D_

_x000D_

#Access Your Free Sample Report For In-Depth Market Analysis:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report_x000D_

_x000D_

What Key Factors Are Affecting The Non-Alcoholic Steatohepatitis Biomarkers Market Demand?_x000D_

An increasing incidence of liver cancer is projected to boost the expansion of the non-alcoholic steatohepatitis biomarkers market moving ahead. Liver cancer involves the formation of cancerous growths within the liver, originating either within the organ itself (primary) or spreading to it from elsewhere in the body (secondary or metastatic). Non-alcoholic steatohepatitis (NASH) biomarkers find application in liver cancer management for purposes such as early identification, tracking disease advancement, evaluating treatment efficacy, offering prognostic data, and potentially lessening the requirement for invasive interventions. For example, reports from July 2025, citing the UK-based cancer journal ecancer medical science, previously forecast that new liver cancer diagnoses are predicted to nearly double, rising from 870,000 in 2022 to 1.52 million by 2050. This surge is primarily attributed to population growth and ageing populations, with the most significant increases expected in Africa. Furthermore, fatalities from liver cancer are also anticipated to climb from 760,000 in 2022 to 1.37 million by 2050. Consequently, the escalating incidence of liver cancer is a key factor propelling the expansion of the non-alcoholic steatohepatitis biomarkers market._x000D_

_x000D_

What Are The Key Segment Divisions In The Non-Alcoholic Steatohepatitis Biomarkers Market Segment Structure?_x000D_

The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types_x000D_

2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies_x000D_

3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses_x000D_

_x000D_

Subsegments:_x000D_

1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index _x000D_

2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin _x000D_

3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP) _x000D_

4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP) _x000D_

5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers _x000D_

_x000D_

What Trends Are Influencing Changes In The Non-Alcoholic Steatohepatitis Biomarkers Market?_x000D_

Leading companies in the non-alcoholic steatohepatitis biomarkers market are integrating advanced biomarker-platform technologies, such as multi-analyte fibrosis-scoring assays, to improve non-invasive disease assessment and patient risk stratification. These assays examine multiple fibrosis-related proteins within a single blood sample and utilize an algorithm to generate a numerical score, which allows for prognostic evaluation and assists in identifying advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical-technology company, secured breakthrough device designation from the US Food and Drug Administration for its Enhanced Liver Fibrosis Test. This test is a multi-analyte fibrosis-scoring assay aimed at supporting the identification of advanced fibrosis and cirrhosis in individuals with non-alcoholic fatty liver disease, featuring a numerical score derived from three direct fibrosis biomarkers. The test facilitates earlier clinical evaluation of liver disease severity and decreases dependency on invasive biopsy._x000D_

_x000D_

Which Organizations Are Engaged In The Non-Alcoholic Steatohepatitis Biomarkers Market?_x000D_

Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine _x000D_

_x000D_

#Get The Full Non-Alcoholic Steatohepatitis Biomarkers Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report_x000D_

_x000D_

Which Region Leads The Non-Alcoholic Steatohepatitis Biomarkers Market In Terms Of Market Share?_x000D_

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Non-Alcoholic Steatohepatitis Biomarkers Market Report For Competitive Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2026, By The Business Research Company#_x000D_

_x000D_

Non Alcoholic Steatohepatitis Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report_x000D_

_x000D_

Non Alcoholic Steatohepatitis Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report_x000D_

_x000D_